




Searching News Database: leuprolide
HSMN NewsFeed - 4 May 2020
Enteris BioPharma Appoints Rajiv Khosla, Ph.D., as Chief Executive Officer
Enteris BioPharma Appoints Rajiv Khosla, Ph.D., as Chief Executive Officer
HSMN NewsFeed - 10 Feb 2020
Enteris BioPharma Appoints Gary A. Shangold, MD, as Chief Medical Officer
Enteris BioPharma Appoints Gary A. Shangold, MD, as Chief Medical Officer
HSMN NewsFeed - 11 Feb 2019
Foresee Pharmaceuticals Enters Exclusive License Agreement with Accord Healthcare
Foresee Pharmaceuticals Enters Exclusive License Agreement with Accord Healthcare
HSMN NewsFeed - 27 Sep 2017
Foresee Pharmaceuticals and TRPharm Announce License and Distribution Agreement
Foresee Pharmaceuticals and TRPharm Announce License and Distribution Agreement
HSMN NewsFeed - 27 Feb 2012
European Commission Approves Esmya(R) for the Pre-Operative Treatment of Uterine Fibroids (myomas)
European Commission Approves Esmya(R) for the Pre-Operative Treatment of Uterine Fibroids (myomas)
HSMN NewsFeed - 2 Jun 2011
Soligenix Appoints Joseph Warusz as Vice President of Administration and Controller
Soligenix Appoints Joseph Warusz as Vice President of Administration and Controller
HSMN NewsFeed - 29 Jun 2009
DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation
DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation
HSMN NewsFeed - 18 Mar 2009
FIRMAGON(R) (Degarelix) is Launched in Europe for the Treatment of Advanced Prostate Cancer
FIRMAGON(R) (Degarelix) is Launched in Europe for the Treatment of Advanced Prostate Cancer
HSMN NewsFeed - 13 Mar 2009
DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer
DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer
HSMN NewsFeed - 6 Jan 2009
DOR BioPharma Obtains Fast Track Designation for DOR201 in the Prevention of Acute Radiation Enteritis
DOR BioPharma Obtains Fast Track Designation for DOR201 in the Prevention of Acute Radiation Enteritis
HSMN NewsFeed - 22 May 2008
DOR BioPharma Provides Update on orBec(R) European Regulatory and Development Strategy
DOR BioPharma Provides Update on orBec(R) European Regulatory and Development Strategy
HSMN NewsFeed - 20 Dec 2007
Marketing of Viadur(R) (leuprolide acetate implant) to Phase Out by April 2008
Marketing of Viadur(R) (leuprolide acetate implant) to Phase Out by April 2008
HSMN NewsFeed - 7 Dec 2007
DOR BioPharma Announces Results of orBec(R) End of Review Conference With the FDA
DOR BioPharma Announces Results of orBec(R) End of Review Conference With the FDA
HSMN NewsFeed - 9 Oct 2007
orBec(R) Clinical Summary Published in "Expert Opinion on Investigational Drugs"
orBec(R) Clinical Summary Published in "Expert Opinion on Investigational Drugs"
HSMN NewsFeed - 31 Aug 2007
Eligard(R) six-month formulation successfully completes European approval procedure
Eligard(R) six-month formulation successfully completes European approval procedure
HSMN NewsFeed - 9 May 2007
FDA Advisory Panel Reviews DOR BioPharma's orBec(R) for Treatment of GI GVHD
FDA Advisory Panel Reviews DOR BioPharma's orBec(R) for Treatment of GI GVHD
HSMN NewsFeed - 4 Apr 2007
DOR BioPharma Announces Initiation of Clinical Development Program for Oral Leuprolide
DOR BioPharma Announces Initiation of Clinical Development Program for Oral Leuprolide
HSMN NewsFeed - 24 Oct 2006
Repros Reports Partial Interim Assessment of Phase 2 Study of Proellex(TM) in Endometriosis
Repros Reports Partial Interim Assessment of Phase 2 Study of Proellex(TM) in Endometriosis
HSMN NewsFeed - 3 May 2006
Voyager Pharmaceutical Corporation Completes Second Phase II Clinical Study for Alzheimer's Disease
Voyager Pharmaceutical Corporation Completes Second Phase II Clinical Study for Alzheimer's Disease
Additional items found! 46

Members Archive contains
46 additional stories matching:
leuprolide
(Password required)
leuprolide
(Password required)